Compare RVPH & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | ASPS |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 73.9M |
| IPO Year | N/A | N/A |
| Metric | RVPH | ASPS |
|---|---|---|
| Price | $0.34 | $5.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $3.14 | N/A |
| AVG Volume (30 Days) | ★ 8.3M | 21.8K |
| Earning Date | 11-13-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $169,648,000.00 |
| Revenue This Year | N/A | $38.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $947.25 |
| Revenue Growth | N/A | ★ 10.68 |
| 52 Week Low | $0.25 | $4.92 |
| 52 Week High | $2.15 | $15.96 |
| Indicator | RVPH | ASPS |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 32.14 |
| Support Level | $0.32 | $6.80 |
| Resistance Level | $0.39 | $7.45 |
| Average True Range (ATR) | 0.04 | 0.48 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 66.36 | 14.12 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.